136 related articles for article (PubMed ID: 32212801)
1. Effect of Metformin For Decreasing Proliferative Marker in Women with Endometrial Cancer: A Randomized Double-blind Placebo-Controlled Trial.
Petchsila K; Prueksaritanond N; Insin P; Yanaranop M; Chotikawichean N
Asian Pac J Cancer Prev; 2020 Mar; 21(3):733-741. PubMed ID: 32212801
[TBL] [Abstract][Full Text] [Related]
2. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer.
Laskov I; Drudi L; Beauchamp MC; Yasmeen A; Ferenczy A; Pollak M; Gotlieb WH
Gynecol Oncol; 2014 Sep; 134(3):607-14. PubMed ID: 24972190
[TBL] [Abstract][Full Text] [Related]
3. PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial.
Kitson SJ; Maskell Z; Sivalingam VN; Allen JL; Ali S; Burns S; Gilmour K; Latheef R; Slade RJ; Pemberton PW; Shaw J; Ryder WD; Kitchener HC; Crosbie EJ
Clin Cancer Res; 2019 Apr; 25(8):2424-2432. PubMed ID: 30563932
[TBL] [Abstract][Full Text] [Related]
4. Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
Sivalingam VN; Kitson S; McVey R; Roberts C; Pemberton P; Gilmour K; Ali S; Renehan AG; Kitchener HC; Crosbie EJ
Br J Cancer; 2016 Feb; 114(3):281-9. PubMed ID: 26794276
[TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.
Soliman PT; Zhang Q; Broaddus RR; Westin SN; Iglesias D; Munsell MF; Schmandt R; Yates M; Ramondetta L; Lu KH
Gynecol Oncol; 2016 Dec; 143(3):466-471. PubMed ID: 27745917
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.
Schuler KM; Rambally BS; DiFurio MJ; Sampey BP; Gehrig PA; Makowski L; Bae-Jump VL
Cancer Med; 2015 Feb; 4(2):161-73. PubMed ID: 25417601
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial.
Mitsuhashi A; Kiyokawa T; Sato Y; Shozu M
Cancer; 2014 Oct; 120(19):2986-95. PubMed ID: 24917306
[TBL] [Abstract][Full Text] [Related]
9. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines.
Laskov I; Abou-Nader P; Amin O; Philip CA; Beauchamp MC; Yasmeen A; Gotlieb WH
Int J Gynecol Cancer; 2016 Sep; 26(7):1213-21. PubMed ID: 27643646
[TBL] [Abstract][Full Text] [Related]
10. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.
Løvvik TS; Carlsen SM; Salvesen Ø; Steffensen B; Bixo M; Gómez-Real F; Lønnebotn M; Hestvold KV; Zabielska R; Hirschberg AL; Trouva A; Thorarinsdottir S; Hjelle S; Berg AH; Andræ F; Poromaa IS; Mohlin J; Underdal M; Vanky E
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):256-266. PubMed ID: 30792154
[TBL] [Abstract][Full Text] [Related]
11. The evolving role of targeted metformin administration for the prevention and treatment of endometrial cancer: A systematic review and meta-analysis of randomized controlled trials.
Prodromidou A; Lekka S; Fotiou A; Psomiadou V; Iavazzo C
J Gynecol Obstet Hum Reprod; 2021 Nov; 50(9):102164. PubMed ID: 33992830
[TBL] [Abstract][Full Text] [Related]
12. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
Bonanni B; Puntoni M; Cazzaniga M; Pruneri G; Serrano D; Guerrieri-Gonzaga A; Gennari A; Trabacca MS; Galimberti V; Veronesi P; Johansson H; Aristarco V; Bassi F; Luini A; Lazzeroni M; Varricchio C; Viale G; Bruzzi P; Decensi A
J Clin Oncol; 2012 Jul; 30(21):2593-600. PubMed ID: 22564993
[TBL] [Abstract][Full Text] [Related]
13. Metformin intervention in obese non-diabetic patients with breast cancer: phase II randomized, double-blind, placebo-controlled trial.
Ko KP; Ma SH; Yang JJ; Hwang Y; Ahn C; Cho YM; Noh DY; Park BJ; Han W; Park SK
Breast Cancer Res Treat; 2015 Sep; 153(2):361-70. PubMed ID: 26293146
[TBL] [Abstract][Full Text] [Related]
14. Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling.
Zhao Y; Sun H; Feng M; Zhao J; Zhao X; Wan Q; Cai D
Gynecol Endocrinol; 2018 May; 34(5):428-432. PubMed ID: 29182407
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin.
Sivalingam VN; Latif A; Kitson S; McVey R; Finegan KG; Marshall K; Lisanti MP; Sotgia F; Stratford IJ; Crosbie EJ
Br J Cancer; 2020 Jan; 122(1):62-71. PubMed ID: 31819173
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
17. The benefits of adding metformin to tamoxifen to protect the endometrium-A randomized placebo-controlled trial.
Davis SR; Robinson PJ; Jane F; White S; Brown KA; Piessens S; Edwards A; McNeilage J; Woinarski J; Chipman M; Bell RJ
Clin Endocrinol (Oxf); 2018 Nov; 89(5):605-612. PubMed ID: 30107043
[TBL] [Abstract][Full Text] [Related]
18. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
Higurashi T; Hosono K; Takahashi H; Komiya Y; Umezawa S; Sakai E; Uchiyama T; Taniguchi L; Hata Y; Uchiyama S; Hattori A; Nagase H; Kessoku T; Arimoto J; Matsuhashi N; Inayama Y; Yamanaka S; Taguri M; Nakajima A
Lancet Oncol; 2016 Apr; 17(4):475-483. PubMed ID: 26947328
[TBL] [Abstract][Full Text] [Related]
19. Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial.
Dodd JM; Louise J; Deussen AR; Grivell RM; Dekker G; McPhee AJ; Hague W
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):15-24. PubMed ID: 30528218
[TBL] [Abstract][Full Text] [Related]
20. Improving treatment for obese women with early stage cancer of the uterus: rationale and design of the levonorgestrel intrauterine device ± metformin ± weight loss in endometrial cancer (feMME) trial.
Hawkes AL; Quinn M; Gebski V; Armes J; Brennan D; Janda M; ; Obermair A
Contemp Clin Trials; 2014 Sep; 39(1):14-21. PubMed ID: 24999075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
